A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

Severe obesity in childhood and adolescence more than triples the risk of MS, and obesity treatment does not seem to reverse it, a study finds.

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

About 5% of people who catch COVID have long-lasting symptoms. In these people, loss of smell, dizziness, fatigue and other hallmark COVID symptoms can persist for months after the initial illness.